Market News How it works Learn FAQ
| RCT 0.0923 21.29% | NU 12.5021 -17.53% | EWZ 34.02 -20.12% | BBD 2.877 -29.31% | TGL 0.2429 9.66% | AZTR 2.05 186.71% | ITUB 7.68 -20.58% | SRTM 0.2775 -35.51% | NVD 3.995 -4.65% | XP 15.4801 -49.10% | WFF 0.089 11.25% | SHFS 0.091 -31.27% | SPCX 149.37 1.27% | SOXL 92.37 10.54% | PBR 22.715 -13.17% | VALE 11.99 -3.31% | CLRO 4.84 48.92% | INTC 91.75 5.51% | GCDT 0.1443 -18.06% | TSLL 10.885 11.53% | NWGL 0.0872 6.34% | NOK 8.715 7.06% | NVDA 216.1126 2.44% | SOXS 46.95 -10.50% | CRWV 56.22 3.66% | BITO 10.695 -1.25% | RWM 14.475 -0.52% | GPUS 0.1858 10.01% | SGRY 23.185 47.21% | TSLG 5.445 11.81% | ABEV 2.805 -15.00% | JBLU 2.285 -12.95% | IREN 26.025 4.50% | INTR 4.595 -36.09% | RBNE 0.1682 -11.47% | QID 14.1701 -2.61% | AAL 12.1792 0.57% | TQQQ 68.8286 3.83% | SBS 4.6303 -27.65% | SPDN 8.485 -0.64% | TSLA 393.84 5.81% | T 20.6998 -1.10% | LUCD 0.538 30.90% | SID 0.9075 -23.09% | WULF 12.3201 8.83% | XTND 2.2899 29.37% | NFLX 63.005 -4.32% | CIFR 7.885 -0.69% | SQQQ 38.17 -3.81% | RIG 6.555 2.26%
ACAlpha Cognition Inc logo

Alpha Cognition Inc (ACOG)

NASDAQ · Currency in USD
$8.45 ▲ +0.11 (+1.32%)
As of Oct 26, 3:23 PM ET. Market open.

Summary

Previous Close
$8.34
Open
$8.32
Day's Range
$8.08 – $8.45
52 Week Range
$4.50 – $10.14
Volume
70,331
Avg. Volume
111,472
Market Cap
$131.24M
Beta (5Y Monthly)
2.23
PE Ratio (TTM)
--
EPS (TTM)
-$1.08
Earnings Date
Nov 12, 2026
Forward Dividend & Yield
--
Ex-Dividend Date
--
1y Target Est
$17.25

Profile: Alpha Cognition Inc

Sector
Healthcare
Industry
Biotechnology
Full-time employees
71
CEO
Michael E. McFadden

Alpha Cognition Inc., a biopharmaceutical company, engages in the development of treatments for patients suffering from neurodegenerative diseases in the United States and Canada. The company's commercial development program includes ZUNVEYL oral tablet formulation for treating Alzheimer's disease. Its pre-clinical development programs comprise ZUNVEYL in combination with memantine for the treatment of moderate-to-severe Alzheimer's disease; ALPHA-1062 sublingual formulation for acute pancreatitis; ALPHA-1062 intranasal formulation for the treatment of cognitive impairment with mild traumatic brain injury; and ALPHA-0602, ALPHA-0702, and ALPHA-0802 programs for the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis disease and spinal muscular atrophy.

Earnings

Next report: Thu, Nov 12, 2026
EPS estimate -$0.33 · Revenue est. $7.04M
DateEst.Actual
Aug 13, 2026-$0.39-$0.40Miss
May 14, 2026-$0.41-$0.37Beat
Mar 26, 2026-$0.27-$0.30Miss
Nov 13, 2025-$0.43-$0.08Beat
Aug 14, 2025-$0.46-$0.65Miss
May 15, 2025-$0.58-$0.20Beat

Analyst view

Consensus price target
$17.25 ▲ +104.1%
Range $12.00 – $20.00
Rating: Buy
Buy 100% · Hold 0% · Sell 0%

Get free alerts on ACOG and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.